Solid Tumors
Solid Tumor
Profile
434
Genes
-
TAT
5-7 Days -
Indications
All solid tumors:
Mutations in 434 genes,
copy number variation and chromosomal structural abnormalities,
TMB, MSI, HRD
- -
Sample Type
FFPE -
Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
DNA -
Diagnostic
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor Fusion / Expression Profile
1408
Genes
-
TAT
7-10 Days -
Indications
ALL Solid tumors:
Fusion: ALK, ROS1, RET, NTRK1/2/3, FGFR1/2/3/4, BRAF, CIC, EWSR1 and other sarcoma genes
Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67,
ERBB2, MDM2
Alternative splicing: MET exon 14 skipping, EGFR vIII , NTRK
Mutations in all 1400 genes -
Sample Type
FFPE -
Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
RNA -
Diagnostic
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor
Profile Plus
434/1408
Genes
-
TAT
7-10 Days -
Indications
ALK, ROS1, RET, NTRK1/2/3, BRAF, CIC, EWSR1, PD-L1,
MET exon 14 skipping and various alternative splicing,
MET, HER2,
EGFR amplification,
PIK3CA, PTEN, AKT1, RAS, HRD
- -
Sample Type
FFPE -
Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
DNA+RNA -
Diagnostic
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
PLUS
Solid Tumor
Monitoring
275
Genes
-
TAT
5-7 Days -
Indications
Monitoring therapy,
resistance and relapse
- -
Sample Type
Peripheral blood -
Sample Requirements
Peripheral blood: 5-10 ml.
EDTA tube preferred -
Results Reported
DNA -
Monitoring
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
Liquid Biopsy
Hematology
Hematology
Profile
179
Genes
-
TAT
5-7 Days -
Indications
MDS, CMML, AML, MPN (JAK2, CALR, MPL), MRD, lymphoma, multiple myeloma, other hematologic diseases
- -
Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue -
Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
DNA -
Diagnostic
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
Liquid Biopsy
Hematology Profile
179
Genes
-
TAT
5-7 Days -
Indications
cfDNA - MDS, CMML, AML, MPN, lymphoma, MRD
- -
Sample Type
Peripheral blood -
Sample Requirements
Peripheral blood: 5-10 ml.
EDTA tube preferred
- -
Results Reported
DNA -
Diagnostic
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
Hematology Fusion /
Expression Profile
1408
Genes
-
TAT
7-10 Days -
Indications
ALL hematologic neoplasms:
Fusion: BCR-ABL1, FIP1L1-PDGFRA, ETV6-RUNX1, PML-RARA, RUNX1-RUNX1T1, ALL-Ph-Like fusions
Expression: PD-L1, B-cell markers, T-cell markers, myeloid markers, KI67, MYC, BCL2, BCL6, BCL1, BCMA, PAX5
alternative splicing, Mutations in all 1400 genes -
Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue -
Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
RNA -
Diagnostic
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
Hematology
Profile Plus
179/1408
Genes
-
TAT
7-10 Days -
Indications
Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia
Includes IgVH
- -
Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue -
Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
DNA+RNA -
Diagnostic
-
Therapeutic
-
Prognostic
-
Heterogeneity
-
Clinical Trial Matching
Read More
Learn more about this test
PLUS